A review by the US Office of Inspector General found that only about half of the scientists running clinical trials funded by the NIH in 2019 and 2020 appropriately recorded their findings in a federal database, as is legally required.
The announcement confirms earlier reports that Bertagnolli will become the first woman to lead the National Cancer Institute since its founding in 1937.
A new presidential memorandum requires the Department of Health and Human Services to coordinate a government-wide push to generate a research action plan for the condition.
The retracted studies were coauthored by a scientist who worked on an Alzheimer’s therapy in development by Cassava Sciences, a company reportedly under investigation for providing falsified data to the FDA.
The legislation, passed by the House of Representatives yesterday, will increase research agencies’ budgets by around 5 percent in 2022 and support the creation of a new health agency.
In a win for the US Department of Justice’s China Initiative, Charles Lieber was convicted of hiding his financial ties to China from federal agencies.
The glycoprotein researcher and longtime principal deputy director of the National Institutes of Health will take over from Francis Collins on December 20.
The revision allows more time on previous extensions due to COVID-19 and other life events such as childbirth that disproportionately impact early-career women in science.
The NIH shared new data detailing complaints it has received in recent years, the latest in a series of steps taken by funding agencies and professional organizations to address misconduct.
A new ruling removes the requirement that grants and proposals using the material receive approval from an ethical review board, reverting to the process in place before 2019.
A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as “provisionally accepted” on the journal’s website before being removed this week.
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Almost 60 percent of people in a new study on attitudes in the US felt comfortable using animals to grow human organs from induced pluripotent stem cells.
